Endothelial Glycocalyx Damage in Brain Death Organ Donors

Organ Transplant Failure or Rejection Clinical Trial

Official title:

Endothelial Glycocalyx Status and Damage in Brain Death Organ Donors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05609123
• Other study ID #: CooperatioUK_DBD_GCX
• Status: Recruiting
• Start date: January 1, 2022
• Est. completion date: December 31, 2024

Study information

• Verified date: May 2024
• Source: University Hospital Hradec Kralove
• Contact: David Astapenko, MD, PhD
• Phone: +420495833218
• Email: david.astapenko[@]fnhk.cz
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The study aims the assessment of endothelial glycocalyx (EG) degradation in deceased organ donors. There is a lack of organs for the transplantation program. By the description of the EG status, we can open room for organ optimization before transplantation and improve the organ function after transplantation in marginal donors.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• patients in critical condition declared as brain dead by clinical examination

Exclusion Criteria:

• N/A

Related Conditions & MeSH terms

• Brain Death
• Brain Injuries
• Hypoxia
• Organ Donors
• Organ Transplant Failure or Rejection

Intervention

Diagnostic Test:
• Endothelial glycocalyx damage assessment
Degradation products of endothelial glycocalyx will be assessed in the blood and urine.

Locations

Country	Name	City	State
Czechia	University Hospital Hradec Kralove	Hradec Kralove

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital Hradec Kralove

Country where clinical trial is conducted

Czechia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Markers of endothelial glycocalyx damage	Levels of syndecan-1 in serum and urine	baseline at the time of inclusion